Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemo…
| Periodo | 2027-02 | 2026-07 | 2025-07 | 2024-07 |
|---|---|---|---|---|
| Real | — | $0.17 | $0.22 | $0.15 |
| Estimado | — | $0.28 | $0.28 | $0.23 |
| Sorpresa | — | -39.3% | -21.4% | -34.8% |
| Métrica | GRFS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 38.8% | 57.4% | -18.6% |
| Operating Margin | 16.5% | -34.4% | +50.9% |
| Net Margin | 2.2% | -32.5% | +34.6% |
| FCF Margin | 9.3% | -12.6% | +21.9% |
| ROE | 2.7% | -39.2% | +41.8% |
| ROA | 0.7% | -30.9% | +31.7% |
| Current Ratio | 2.66 | 2.73 | -0.07 |
| Debt / Equity | 0.40 | 0.28 | +0.12 |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 0.7% | — |
| ✓Flujo de caja operativo positivo | €902M | €219M |
| ✓Rentabilidad sobre activos al alza | 0.7% | 0.2% |
| ✓Caja operativa/activos supera al ROA | 4.2% | ROA 0.7% |
| ✓Menos deuda a largo plazo | 10.9% | 17.4% |
| ✓Mejor liquidez (ratio corriente) | 2.66 | 2.64 |
| ✗Sin aumentar el nº de acciones | 680M | 677M |
| ✓Margen bruto al alza | 38.7% | 37.7% |
| ✓Rotación de activos al alza | 0.34 | 0.31 |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | 9.3% |
| ✗ROCE > 10 % | 6.2% |
| ✓Ventas > 5 %/año (3 años) | 13.5% |
| ✓Deuda neta/EBITDA < 3x | 1.0x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 8.5% |
Grifols SA cotiza a 7.64 USD y tiene una capitalización bursátil de $5.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud